# Efficacy of External Siddha Pharmacotherapy for Giant Acrochordon: A Case Report

**Authors:** Saravanasingh Karan Chand Mohan Singh, Sugumaran Pichamuthu, V Gowri, Murugesan Sannasi, Chenthamarai Selvi G

PMC · DOI: 10.7759/cureus.84012 · Cureus · 2025-05-13

## TL;DR

A 50-year-old man successfully treated a large skin tag using Pachaieruvai, a traditional Siddha medicine, with no recurrence after six months.

## Contribution

Demonstrates the potential efficacy of Pachaieruvai, a traditional Siddha medicine, for treating giant acrochordons as a non-surgical alternative.

## Key findings

- The lesion was completely resolved within 15 days of applying Pachaieruvai.
- No recurrence or complications were observed during follow-up evaluations up to six months.
- Pachaieruvai contains ingredients like arsenic trioxide and copper sulfate, which may target abnormal cell growth.

## Abstract

Giant acrochordons, commonly referred to as skin tags, are benign, pedunculated lesions often linked to conditions such as obesity, diabetes, and metabolic syndrome. While these lesions are generally harmless, they can lead to discomfort or cosmetic concerns, prompting individuals to seek treatment. Traditional methods, including excision and cryotherapy, are frequently employed but come with certain risks. This study explores the use of Pachaieruvai, a traditional Siddha medicine, as an alternative treatment option. The subject of this report was a 50-year-old male who had a large skin tag on his gluteal region that had been growing for 15 years. Opting for Pachaieruvai over surgery, he applied the topical preparation for 10 days. Remarkably, the lesion was completely resolved within 15 days, and follow-up evaluations at two weeks, three weeks, and six months showed no recurrence or complications. Pachaieruvai comprises five ingredients recognized for their cytotoxic properties, including arsenic trioxide and copper sulfate, which may assist in targeting abnormal cell growth. However, the study's small sample size, absence of controlled trials, and potential safety concerns regarding arsenic necessitate further research to validate its efficacy and establish standardized treatment protocols.

## Linked entities

- **Chemicals:** arsenic trioxide (PubChem CID 14888), copper sulfate (PubChem CID 24462)
- **Diseases:** obesity (MONDO:0011122), diabetes (MONDO:0005015), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Diseases:** Giant acrochordons (MESH:D058249), cytotoxic (MESH:D064420), skin tags (MESH:C566904), metabolic syndrome (MESH:D024821), obesity (MESH:D009765), diabetes (MESH:D003920)
- **Chemicals:** arsenic trioxide (MESH:D000077237), arsenic (MESH:D001151), copper sulfate (MESH:D019327), Pachaieruvai (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12160067/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12160067/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12160067/full.md

---
Source: https://tomesphere.com/paper/PMC12160067